124 related articles for article (PubMed ID: 38142841)
1. The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis.
Buonvicino D; Pratesi S; Ranieri G; Pistolesi A; Guasti D; Chiarugi A
Neurobiol Dis; 2024 Feb; 191():106387. PubMed ID: 38142841
[TBL] [Abstract][Full Text] [Related]
2. Early derangement of axonal mitochondria occurs in a mouse model of progressive but not relapsing-remitting multiple sclerosis.
Buonvicino D; Ranieri G; Guasti D; Pistolesi A; La Rocca AI; Rapizzi E; Chiarugi A
Neurobiol Dis; 2023 Mar; 178():106015. PubMed ID: 36702320
[TBL] [Abstract][Full Text] [Related]
3. Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution.
Buonvicino D; Ranieri G; Pratesi S; Guasti D; Chiarugi A
Exp Neurol; 2019 Dec; 322():113065. PubMed ID: 31536728
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis.
Buonvicino D; Ranieri G; Pratesi S; Gerace E; Muzzi M; Guasti D; Tofani L; Chiarugi A
Br J Pharmacol; 2020 Jul; 177(14):3342-3356. PubMed ID: 32199028
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway.
Hou H; Miao J; Cao R; Han M; Sun Y; Liu X; Guo L
Neurochem Res; 2017 Oct; 42(10):2831-2840. PubMed ID: 28600752
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
Bonfiglio T; Olivero G; Merega E; Di Prisco S; Padolecchia C; Grilli M; Milanese M; Di Cesare Mannelli L; Ghelardini C; Bonanno G; Marchi M; Pittaluga A
PLoS One; 2017; 12(1):e0170825. PubMed ID: 28125677
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis.
Buonvicino D; Ranieri G; Chiarugi A
Neuroscience; 2021 Jun; 465():38-45. PubMed ID: 33862148
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
[TBL] [Abstract][Full Text] [Related]
9. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
Camacho-Toledano C; Machín-Díaz I; Calahorra L; Cabañas-Cotillas M; Otaegui D; Castillo-Triviño T; Villar LM; Costa-Frossard L; Comabella M; Midaglia L; García-Domínguez JM; García-Arocha J; Ortega MC; Clemente D
J Neuroinflammation; 2022 Nov; 19(1):277. PubMed ID: 36403026
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn.
Doolen S; Iannitti T; Donahue RR; Shaw BC; Grachen CM; Taylor BK
Pain; 2018 Feb; 159(2):224-238. PubMed ID: 29140922
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D
Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
Hou H; Cao R; Quan M; Sun Y; Sun H; Zhang J; Li B; Guo L; Song X
J Neuroimmunol; 2018 Nov; 324():26-34. PubMed ID: 30205205
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
[TBL] [Abstract][Full Text] [Related]
16. The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data.
Vakrakou AG; Alexaki A; Brinia ME; Anagnostouli M; Stefanis L; Stathopoulos P
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897651
[TBL] [Abstract][Full Text] [Related]
17. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy.
Huehnchen P; Boehmerle W; Endres M
Sci Rep; 2018 Apr; 8(1):5648. PubMed ID: 29618748
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Evening Primrose/Hemp Seed Oil Compared to Rapamycin on the Gene Expression of Immunological Parameters in Experimental Autoimmune Encephalomyelitis Splenocytes.
Rezapour-Firouzi S; Mohammadian M; Sadeghzadeh M; Mehranfar S; Mazloomi E
Iran J Allergy Asthma Immunol; 2020 Apr; 19(2):183-192. PubMed ID: 32372631
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.
Silva RBM; Greggio S; Venturin GT; da Costa JC; Gomez MV; Campos MM
Mol Neurobiol; 2018 Dec; 55(12):9307-9327. PubMed ID: 29667130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
